IMV, through its subsidiary, ImmunoVaccine Technologies Inc., is a clinical stage biopharmaceutical company that develops products based on its proprietary vaccine enhancement platform with a primary focus on T cell activating therapies for cancers. Co. also capitalizes on licensing opportunities of its platform for other applications including infectious diseases. Co.'s proprietary DepoVax™ adjuvanting/delivery platform is believed to produce an immune response that has a specific and sustained immune effect, and enables Co. to pursue vaccine candidates in cancer, infectious diseases and potentially other vaccine applications. We show 2 historical shares outstanding datapoints in our IMV shares outstanding history coverage, used to compute IMV market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing IMV market cap history over the course of time is important for investors
interested in comparing IMV's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of IMV versus a peer is one thing; comparing
IMV market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like IMV can fluctuate over the course of history.
With this page we aim to empower investors researching IMV by allowing them to research the IMV market cap history. |
Free IMV Email Alerts:
Video: The Importance of Market Cap
